Skip to main content
. 2021 Mar 2;10(3):372. doi: 10.3390/antiox10030372

Figure 1.

Figure 1

Tau-Cl suppressed infarct formation in the postischemic brain. (A,B) Tau-Cl (0.1, 0.5, 1 or 2 mg/kg) or taurine (0.5 or 1 mg/kg) was administered intranasally at 1 h post- middle cerebral artery occlusion (MCAO) and 2,3,5-triphenyl tetrazolium chloride (TTC) staining was carried out at 2 days post-MCAO. (C,D) Tau-Cl (0.5 mg/kg) was administered intranasally at 1 h prior to or 1 or 4 h post-MCAO, and TTC staining was carried out at 2 days post-MCAO. Representative images of infarctions are shown (A,C), and mean infarction volumes are presented as mean ± SEM (n = 4–10) (B,D). Sham, sham-operated rats (n = 4); MCAO, PBS-treated MCAO control (n = 10); MCAO + Tau-Cl, Tau-Cl-treated MCAO rats (n = 33); MCAO + Taurine, taurine-treated MCAO rats (n = 8). * p < 0.05, ** p < 0.01 vs. PBS-treated MCAO control by one-way ANOVA with Student–Newman–Keuls test.